Body Systems

Acute Myeloid Leukemia4 Results found

(VALOR)…

This study will compare the overall survival (OS) between treatment groups of patients treated with vosaroxin and cytarabine versus patients treated with placebo and cytarabine.

Principal Investigator 
Donna E. Hogge
Body Locations and Systems 
Leukemia
Area 
Vancouver
Age 
18 and above

(QuANTUM-R): An Open-label Study of Quizartinib Monotherapy vs. Salvage Chemotherapy in Acute Myeloid Leukemia (AML) Subjects Who Are FLT3-ITD Positive

The primary objective of the study is to determine whether quizartinib monotherapy prolongs overall survival (OS) compared to salvage chemotherapy in subjects with FMS-like tyrosine kinase 3 - Internal Tandem Duplication (FLT3-ITD) positive AML who are refractory to or have relapsed within 6 mont

Principal Investigator 
Donna E. Hogge
Body Locations and Systems 
Leukemia
Area 
Vancouver
Age 
18 and above

(301)…

To confirm the efficacy of CPX-351 compared to 7+3 as first line therapy in elderly patients (60-75 yrs) with high risk (secondary) Acute Myeloid Leukemia. The primary efficacy endpoint will be overall survival.

Principal Investigator 
Donna E. Hogge
Body Locations and Systems 
Leukemia
Area 
Vancouver
Age 
60-75

in Chronic Phase Receiving Treatment With Imatinib…

Imatinib (IM) is first-line treatment for patients with newly diagnosed CML in chronic phase. The drug is associated with high rates of cytogenetic responses with minimal toxicity in approximately 80% of patients.

Principal Investigator 
Donna Forrest
Body Locations and Systems 
Leukemia
Area 
Vancouver
Age 
18 and above